Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh | Cancer Cell Biology | Innovative Research Award

Prof. Dalia Saleh, National Research Centre, Egypt

Dr. Dalia Osama Abd El Fattah Saleh is a distinguished pharmacologist and professor at the National Research Centre, Cairo, Egypt. With a career spanning over two decades in academic and pharmaceutical research, she specializes in molecular pharmacology, experimental therapeutics, and drug development. She earned her Ph.D. and M.Sc. in Pharmacology from Cairo University, where she also completed her undergraduate pharmacy degree with honors. Dr. Saleh’s prolific contributions to science are reflected in her extensive publication record, focusing on novel therapeutic strategies against various toxicological, metabolic, and inflammatory disorders. Her collaborative efforts have led to advancements in drug signaling pathways, phytochemical pharmacology, and nanotechnology-based delivery systems. Recognized nationally for her innovation, she has received several prestigious awards. Dr. Saleh continues to shape pharmacological research through her dedication to translational science, mentorship, and participation in international seminars and training programs.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  • Extensive Academic Background: Holds a Ph.D., M.Sc., and B.Sc. in Pharmacology from Cairo University, with a clear focus on endocrine and vascular pharmacology from early in her career.

  • Distinguished Research Record: Authored over 25+ high-impact publications in peer-reviewed journals including Scientific Reports, Toxicology Reports, Biochemistry and Cell Biology, and Environmental Science and Pollution Research.

  • Novel Scientific Contributions:

    • Explores molecular pharmacology through cutting-edge therapeutic approaches like AMPK/mTOR signaling, Nrf2/NF-κB modulation, and natural compound pharmacodynamics.

    • Studies involve both synthetic and phytochemical-based interventions, representing a hybrid and innovative research style.

  • Awards and Recognition:

    • National recognition for her research quality and productivity by the National Research Centre, with awards received in 2015 and 2020.

    • Ranked 24th in the institution for publication volume in 2014—an indicator of sustained output.

  • Global Exposure: Participated in professional training programs at King’s College London, enhancing her knowledge in clinical drug development and data management—an asset for interdisciplinary and translational research.

  • Leadership and Longevity: Promoted through all academic ranks at NRC, from Research Assistant to Professor, demonstrating not only competence but leadership and mentorship over time.

Areas for Improvement:

  • Clinical Translation: While the preclinical research is extensive, initiating clinical trials or translational studies would further strengthen the real-world applicability of her findings.

  • Global Visibility: Although trained internationally, more international speaking engagements, keynote invitations, or editorial roles could enhance global recognition.

  • Interdisciplinary Projects: Expanding collaborations across fields such as bioinformatics or biotechnology could amplify the innovation aspect of her work.

🎓 Education:

Dr. Dalia Saleh obtained all her academic degrees from Cairo University’s esteemed Faculty of Pharmacy. She was awarded her Ph.D. in Pharmacology in 2012 for her thesis examining estrogen’s vascular effects in insulin-resistant, ovariectomized rats. Earlier, she earned her M.Sc. in 2009 with research on rosiglitazone’s effects in streptozotocin-induced vascular changes. Her academic journey began with a B.Sc. in Pharmacy in 2002, graduating with distinction and honors. Her strong educational foundation laid the groundwork for her innovative and interdisciplinary research spanning molecular pharmacology, toxicology, and metabolic disorders. Through continuous professional development, including modules at King’s College London, Dr. Saleh stays aligned with global standards in pharmacological science and clinical drug development. Her educational background combines academic excellence with practical research expertise, making her well-equipped to address complex biomedical challenges.

👩‍🔬 Experience:

Dr. Dalia Saleh has built a progressive research career at Egypt’s National Research Centre, beginning as a Research Assistant in 2003. Over the years, she rose through the ranks to become a Professor in 2022. She previously held positions as Researcher (2012–2017) and Assistant Professor (2017–2022). Throughout her tenure, she has actively contributed to preclinical pharmacology research, focusing on inflammation, neuroprotection, metabolic diseases, and organ toxicity. Her interdisciplinary approach integrates pharmacodynamics, molecular signaling, and therapeutic intervention studies using both synthetic and natural compounds. She has led numerous studies that explore drug mechanisms at cellular and systemic levels, often employing rodent disease models. Dr. Saleh’s active participation in international training (e.g., at King’s College London) highlights her global engagement and commitment to continuous learning. Her career reflects not only research productivity but also leadership in collaborative scientific initiatives and mentoring of emerging researchers.

🏆 Awards & Honors:

Dr. Dalia Saleh has received multiple accolades that underscore her impact in the field of pharmacology. She was honored with the 2020 Scientific Pioneers Award and the 2015 Scientific Encouragement Award from Egypt’s National Research Centre (NRC), recognizing her outstanding research contributions. In 2014, she received institutional recognition for both her high publication output (ranked 24th NRC-wide) and for publishing in a high-impact journal (impact factor 4.067). These achievements highlight her consistent scientific productivity and influence in biomedical research. Dr. Saleh’s awards reflect a career driven by innovation, rigor, and dedication to solving pressing health issues. Her work continues to be widely cited and applied in translational pharmacology, securing her reputation as a leading figure in her discipline. She remains an inspiration to peers and students alike, with a legacy of both scientific excellence and mentorship.

🔬 Research Focus:

Dr. Dalia Saleh’s research is rooted in experimental pharmacology, with an emphasis on cell signaling pathways, drug discovery, and natural compound pharmacodynamics. She investigates molecular mechanisms underlying chronic diseases such as diabetes, hepatic and renal injury, neurodegeneration, and inflammatory disorders. A recurring theme in her work is the modulation of key signaling axes (e.g., AMPK/mTOR, NF-κB, PI3K/Akt) in mitigating organ toxicity and disease progression. Her recent studies explore the pharmacological potential of phytochemicals, drug hybrids, and nanoformulations in preclinical models. Dr. Saleh also examines gender-specific pathophysiology, as seen in her Ph.D. research on estrogen’s role in vascular dysfunction. She actively integrates biochemical, histological, and behavioral endpoints to ensure translational relevance. By bridging traditional medicine and molecular pharmacology, her work contributes to next-generation therapeutics and precision medicine. Her research has both national and global impact, frequently published in high-tier journals and cited in clinical research discussions.

📚 Publications Top Notes:

  1. 🧬 Eugenol alleviates acrylamide-induced testicular toxicity via AMPK/pAKT/mTOR signalingScientific Reports, 2024

  2. 💊 Trimetazidine protects against cisplatin-induced neuropathy via AMPK and Nrf2 pathwaysBiochemistry and Cell Biology, 2023

  3. 🧪 Chromone-thiazolopyrimidine hybrids inhibit TNF-α, IL-6, and PGE2Polycyclic Aromatic Compounds, 2023

  4. 🧻 Chrysin counters cyclophosphamide-induced cystitis via STAT-3 and NF-κB inhibitionChemico-Biological Interactions, 2023

  5. 🩺 Linagliptin and L-arginine synergize in hyperacidity via EP4 upregulationNaunyn-Schmiedeberg’s Archives of Pharmacology, 2023

  6. 🧠 L-arginine protects against hepatic encephalopathy via anti-apoptotic mechanismsEnvironmental Science and Pollution Research, 2023

  7. 🌿 Calotropis procera seed oil shows anti-inflammatory and antiparasitic activityArabian Journal of Chemistry, 2022

  8. 🧫 Olmesartan mitigates diabetic nephropathy through TLR4/P38-MAPK modulationEuropean Journal of Pharmacology, 2022

  9. 🌱 Anti-fibrotic activities of Plumbago species in liver fibrosis modelsScientific Reports, 2022

  10. 🐟 Omega-3 fatty acids protect against doxorubicin-induced liver damageSaudi Journal of Biological Sciences, 2022

Conclusion:

Dr. Dalia O. Saleh is highly suitable for the Best Researcher Award based on her prolific scientific contributions, consistent academic progression, and commitment to impactful pharmacological research. Her strength lies in combining rigorous mechanistic studies with applied therapeutic exploration, especially in inflammation, oxidative stress, and natural product pharmacology.

Huizheng Hu | Cancer Cell Biology | Best Researcher Award

Ms. Huizheng Hu | Cancer Cell Biology | Best Researcher Award

Ms. Huizheng Hu , Nuclear Industry 215 Hospital of Shaanxi Province , China

Dr. Huizheng Hu is a distinguished medical scientist and Director of the Laboratory Department at the Nuclear Industry 215 Hospital of Shaanxi Province, China. As an Associate Professor, Dr. Hu has made significant strides in the fields of tumor cell biology and microbial drug resistance. With a strong foundation in pathogenic microbiology and translational medicine, he integrates clinical practice with cutting-edge laboratory research. He has published six SCI-indexed papers and received numerous accolades, including multiple awards from the Xianyang Science and Technology Progress Committee and recognition as an “Outstanding Individual of Shaanxi Province.” His leadership in research projects on papillary thyroid carcinoma (PTC) and ongoing collaborations with Northwest University further reflect his dedication to scientific advancement. Known for his innovation, expertise, and commitment to healthcare, Dr. Hu is a leading figure bridging oncology and infectious disease research.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Research Excellence:
    Dr. Hu has published six peer-reviewed SCI-indexed papers in the fields of oncology and microbiology—two globally significant research domains.

  2. Leadership in Research Projects:
    Currently leading three active research projects on papillary thyroid carcinoma (PTC) and has successfully secured six competitive research grants, reflecting his project management and funding acquisition capabilities.

  3. Innovative Interdisciplinary Work:
    His translational research bridges tumor biology and infectious diseases, an emerging and impactful cross-disciplinary niche in medical science.

  4. Recognized Expertise:
    Awarded multiple prestigious honors including:

    • Third Prize from the Nuclear Industry Geological Exploration Bureau

    • Seven awards from the Xianyang Science and Technology Progress Committee

    • Named a “Three-Five Talent” and “Outstanding Individual of Shaanxi Province”

  5. Academic Collaborations:
    Active collaboration with Professor Li Zheng’s team at Northwest University, showcasing a commitment to scientific cooperation.

🔧 Areas for Improvement:

  1. Global Visibility:
    While regionally recognized, Dr. Hu’s international presence could be enhanced by:

    • Publishing in higher-impact global journals

    • Participating in global scientific conferences or forums

  2. Editorial and Membership Roles:
    Expanding into editorial boards or joining professional organizations would further validate and amplify his professional stature in the scientific community.

  3. Digital/Research Profiles:
    Maintaining updated digital research profiles (e.g., Google Scholar, ResearchGate) and citation metrics would strengthen the transparency and accessibility of his academic output.

🎓 Education:

Dr. Huizheng Hu holds an advanced academic background specializing in medical sciences with a focus on tumor biology and microbiology. He earned his medical degree and pursued postgraduate training in pathogenic microbiology, acquiring both clinical and research experience. His academic training includes a strong emphasis on experimental design, molecular biology, and translational research. Dr. Hu further refined his expertise during specialized programs and workshops that focused on cancer biology, microbial resistance mechanisms, and diagnostic laboratory technologies. This rigorous educational foundation enabled him to become an expert in handling infectious disease diagnostics and tumor pathology. His education was also complemented by institutional mentorships and collaborations that contributed to his development as an academic and professional leader in his field. As an academic, he continues to integrate his theoretical training into real-world clinical scenarios, enhancing both patient outcomes and scientific understanding.

💼 Professional Experience:

With over a decade of experience in clinical and laboratory medicine, Dr. Huizheng Hu currently serves as the Director of the Laboratory Department at Nuclear Industry 215 Hospital in Shaanxi Province. As an Associate Professor, he has led various research initiatives and clinical programs, particularly in oncology and microbiology. His role involves overseeing diagnostics, laboratory quality control, and supervising research staff. Dr. Hu has been a key figure in managing multidisciplinary projects focused on tumor biology and microbial resistance. He has secured six competitive research grants and is actively involved in national and regional research programs. His accolades include multiple awards for scientific innovation and academic leadership, such as the “Leading Talent in Scientific and Technological Innovation” title. Dr. Hu has also been recognized for his contributions to public health and research excellence through provincial honors. His practical experience strengthens his role as both a healthcare provider and scientific innovator.

🔬 Research Focus:

Dr. Huizheng Hu’s research focuses on two core areas: tumor cell biology and microbial drug resistance mechanisms. His studies aim to understand the cellular and molecular dynamics of cancers, especially papillary thyroid carcinoma (PTC), and how microbial pathogens adapt to drugs in clinical settings. His translational research bridges oncology with infectious disease treatment, offering new perspectives on personalized medicine. Currently, Dr. Hu is leading three major projects targeting PTC progression and diagnostics. Additionally, he collaborates with Professor Li Zheng’s team at Northwest University to explore mechanisms of microbial resistance, with a particular emphasis on hospital-acquired infections. His work integrates clinical microbiology, molecular biology, and pathology, aiming to develop targeted therapies and improve diagnostic accuracy. Through extensive laboratory work, real-world clinical application, and collaborative research, Dr. Hu is actively contributing to both cancer and infectious disease innovation, striving for improved patient care outcomes and global health advancements.

📚 Publications Top Notes:

  • 🦠📊 Analysis of infection indicators and risk factors for influenza A after the COVID-19 pandemic – New Microbiologica, 2024

  • 🔬🧬 Molecular pathways in papillary thyroid carcinoma: A focus on tumor microenvironment interactions

  • 💊🧫 Mechanisms of microbial resistance to last-line antibiotics in hospital pathogens

  • 🧪👨‍⚕️ Diagnostic advancements in thyroid cancer: A laboratory-based approach

  • 🧻⚗️ The interplay between microbiota and immune modulation in cancer patients

  • 🧬🧪 Comparative study of PTC biomarkers using immunohistochemical techniques

🧾 Conclusion:

Dr. Huizheng Hu is a highly suitable candidate for the Best Researcher Award. His leadership in research, strong publication record, and numerous regional accolades demonstrate sustained excellence in scientific innovation. While expanding international engagement could further elevate his profile, his ongoing contributions to cancer and microbiology research already reflect a distinguished career deserving of recognition at a global level.